Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4105 USD | +0.12% | +2.73% | -6.68% |
May. 16 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 | |
Apr. 29 | AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.68% | 20.89M | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-0.96% | 21.97B | |
-5.34% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- AIM Stock
- News AIM ImmunoTech Inc.
- AIM ImmunoTech Treats Last Participant in Phase 2 Study of Ampligen for Potential Treatment of Post-COVID Fatigue